LUNG Logo

Pulmonx Corporation (LUNG) 

NASDAQ
Market Cap
$268.12M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
241 of 774
Rank in Industry
33 of 99

Largest Insider Buys in Sector

LUNG Stock Price History Chart

LUNG Stock Performance

About Pulmonx Corporation

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based …

Insider Activity of Pulmonx Corporation

Over the last 12 months, insiders at Pulmonx Corporation have bought $97,436 and sold $1.35M worth of Pulmonx Corporation stock.

On average, over the past 5 years, insiders at Pulmonx Corporation have bought $686,826 and sold $62.68M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Williamson Steven S. (PRESIDENT AND CEO) — $194,872.

The last purchase of 14,245 shares for transaction amount of $97,436 was made by Williamson Steven S. (PRESIDENT AND CEO) on 2024‑08‑20.

List of Insider Buy and Sell Transactions, Pulmonx Corporation

2024-10-17Saledirector
20,000
0.052%
$6.52$130,400+5.62%
2024-09-12Saledirector
20,000
0.0505%
$8.09$161,800-14.30%
2024-09-03SaleCHIEF COMMERCIAL OFFICER
4,586
0.0121%
$6.70$30,721+8.15%
2024-09-03SaleGENERAL COUNSEL
5,765
0.0152%
$6.69$38,576+8.15%
2024-08-20PurchasePRESIDENT AND CEO
14,245
0.0358%
$6.84$97,436+3.24%
2024-06-24SaleCHIEF COMMERCIAL OFFICER
1,184
0.0031%
$6.16$7,293+14.58%
2024-06-03SaleCHIEF COMMERCIAL OFFICER
4,297
0.0112%
$6.97$29,950+0.65%
2024-06-03SaleGENERAL COUNSEL
5,475
0.0142%
$6.97$38,161+0.65%
2024-05-22SaleCHIEF COMMERCIAL OFFICER
1,184
0.003%
$8.71$10,313-22.32%
2024-04-22SaleCHIEF COMMERCIAL OFFICER
1,184
0.0031%
$7.49$8,868-1.35%
2024-03-22SaleCHIEF COMMERCIAL OFFICER
1,184
0.0031%
$9.36$11,082-19.41%
2024-03-01SalePRESIDENT AND CEO
6,954
0.0175%
$9.06$63,003-19.53%
2024-03-01SaleCHIEF COMMERCIAL OFFICER
3,097
0.0078%
$9.06$28,059-19.53%
2024-03-01SaleGENERAL COUNSEL
4,351
0.0109%
$9.06$39,420-19.53%
2024-03-01SaleINTERIM CFO
1,078
0.0027%
$9.06$9,767-19.53%
2024-02-22SaleCHIEF COMMERCIAL OFFICER
1,184
0.0037%
$14.20$16,813-36.64%
2024-02-15SalePRESIDENT AND CEO
20,000
0.052%
$14.60$292,000-48.18%
2024-01-22SaleCHIEF COMMERCIAL OFFICER
1,184
0.003%
$13.13$15,546-41.37%
2024-01-18SalePRESIDENT AND CEO
10,000
0.026%
$12.77$127,700-38.62%
2023-12-22SaleChief Commercial Officer
1,184
0.0031%
$12.75$15,096-36.35%

Insider Historical Profitability

25.7%
Williamson Steven S.PRESIDENT AND CEO
219531
0.5559%
$6.7910
Ferrari Richarddirector
30035
0.0761%
$6.7930+64.56%
Mead Dana G Jr.director
26315
0.0666%
$6.7910<0.0001%
Melenikiotou Georgiadirector
26315
0.0666%
$6.7910<0.0001%
Lynch Alissa Hsudirector
11910
0.0302%
$6.7910+101.97%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
PRIMECAP Management Co$53.2M14.795.74M+1.65%+$861,887.520.04
Fidelity Investments$45M12.514.85M+46.67%+$14.32M<0.01
BlackRock$28.16M7.833.04M-2.56%-$739,718.17<0.01
Point72 Asset Management$25.17M72.72M+75.61%+$10.84M0.04
Morgan Stanley$24.58M6.832.65M+16.36%+$3.46M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.